Danaher Q4 2020 Earnings Report
Key Takeaways
Danaher Corporation reported a strong fourth quarter and full year 2020, marked by a 39.0% increase in revenue for the quarter, driven by 15.5% non-GAAP core revenue growth including Cytiva. Net earnings for the quarter were $1.2 billion, or $1.66 per diluted common share, representing a 55.0% year-over-year increase. The company's non-GAAP adjusted diluted net earnings per common share for the quarter were $2.08, a 62.5% increase over the previous year.
Revenues increased 39.0% year-over-year to $6.8 billion.
Net earnings were $1.2 billion, or $1.66 per diluted common share, a 55.0% increase year-over-year.
Non-GAAP adjusted diluted net earnings per common share were $2.08, a 62.5% increase year-over-year.
Non-GAAP core revenue growth was 15.5% including Cytiva.
Danaher
Danaher
Danaher Revenue by Segment
Forward Guidance
The Company anticipates that non-GAAP core revenue growth including Cytiva will be in the mid to high-teens range for the first quarter 2021 and in the low-double digit range for the full year 2021.
Positive Outlook
- Non-GAAP core revenue growth including Cytiva in the mid to high-teens range for Q1 2021.
- Non-GAAP core revenue growth including Cytiva in the low-double digit range for full year 2021.
- Strong margin expansion.
- More than $5 billion of free cash flow.
- Addition of Cytiva strengthened position as a global science and technology leader.
Challenges Ahead
- Highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic.
- Deterioration of or instability in the economy and the financial markets.
- Contractions or growth rates and cyclicality of markets.
- Potential for improper conduct by employees, agents or business partners.
- Risks relating to potential impairment of goodwill and other intangible assets.
Revenue & Expenses
Visualization of income flow from segment revenue to net income